TABLE 3.
Annual All-Cause and Migraine-Related HCRU at 12-Month Baseline and 12-Month Follow-up Periods (CGRP mAbs vs SOC and GMB vs SOC)
| CGRP mAb vs SOC | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12-month baseline period | 12-month follow-up period | P value (baseline period vs follow-up period) | Mean change (baseline period vs follow-up period), % | P value (mean change) CGRP mAb vs SOC | |||||
| CGRP mAb (N = 3,082) | SOC (N = 3,082) | CGRP mAb (N = 3,082) | SOC (N = 3,082) | CGRP mAb | SOC | CGRP mAb | SOC | ||
| Annual all-cause HCRU | |||||||||
| IP visits | |||||||||
| Patients, n (%) | 210 (6.8) | 302 (9.8) | 204 (6.6) | 217 (7.0) | 0.730 | < 0.001 | −0.200 | −2.800 | 0.003 |
| Visits, mean (SD) | 0.1 (0.4) | 0.1 (0.5) | 0.1 (0.4) | 0.1 (0.4) | 0.901 | < 0.001 | −0.001 | −0.040 | 0.002 |
| ED visits | |||||||||
| Patients, n (%) | 1,087 (35.3) | 1,254 (40.7) | 987 (32.0) | 1,149 (37.3) | 0.001 | 0.001 | −3.200 | −3.400 | 0.911 |
| Visits, mean (SD) | 0.8 (4.9) | 0.9 (1.9) | 0.7 (1.9) | 0.8 (2.1) | 0.033 | 0.009 | −0.200 | −0.100 | 0.399 |
| Annual migraine-related HCRU | |||||||||
| IP visits | |||||||||
| Patients, n (%) | 58 (1.9) | 32 (1.0) | 39 (1.3) | 8 (0.3) | 0.022 | < 0.001 | −0.600 | −0.800 | 0.625 |
| Visits, mean (SD) | 0.02 (0.19) | 0.01 (0.11) | 0.01 (0.14) | 0.004 (0.08) | 0.006 | 0.001 | −0.009 | −0.007 | 0.635 |
| ED visits | |||||||||
| Patients, n (%) | 561 (18.2) | 562 (18.2) | 354 (11.5) | 393 (12.8) | < 0.001 | < 0.001 | −6.700 | −5.500 | 0.270 |
| Visits, mean (SD) | 0.41 (3.90) | 0.30 (0.86) | 0.24 (1.39) | 0.23 (1.36) | 0.006 | 0.001 | −0.200 | −0.100 | 0.115 |
| Acute migraine medication fills | |||||||||
| Patients, n (%) | 2,820 (91.5) | 2,568 (83.3) | 2,676 (86.8) | 2,504 (81.2) | < 0.001 | 0.009 | −4.700 | −2.100 | 0.010 |
| Fills, mean (SD) | 10.00 (12.23) | 6.09 (7.64) | 8.49 (13.35) | 5.86 (7.79) | < 0.001 | 0.024 | −1.500 | −0.200 | < 0.001 |
| Preventive migraine medication fills | |||||||||
| Patients, n (%) | 2,570 (83.4) | 2,406 (78.1) | 2,226 (72.2) | 3,082 (100.0) | < 0.001 | < 0.001 | −11.200 | 21.900 | < 0.001 |
| Fills, mean (SD) | 7.52 (8.11) | 5.05 (6.01) | 6.38 (7.87) | 8.81 (7.62) | < 0.001 | < 0.001 | −1.100 | 3.800 | < 0.001 |
| GMB vs SOC | |||||||||
| 12-month baseline period | 12-month follow-up period | P value (baseline period vs follow-up period) | Mean change (baseline period vs follow-up period), % | P value (mean change) GMB vs SOC | |||||
| GMB (N = 421) | SOC (N = 421) | GMB (N = 421) | SOC (N = 421) | GMB | SOC | GMB | SOC | ||
| Annual all-cause HCRU | |||||||||
| IP visits | |||||||||
| Patients, n (%) | 26 (6.2) | 51 (12.1) | 28 (6.7) | 28 (6.7) | 0.746 | 0.002 | 0.500 | −5.500 | 0.009 |
| Visits, mean (SD) | 0.07 (0.31) | 0.17 (0.61) | 0.09 (0.39) | 0.08 (0.35) | 0.508 | 0.003 | 0.000 | −0.100 | 0.005 |
| ED visits | |||||||||
| Patients, n (%) | 146 (34.7) | 183 (43.5) | 132 (31.4) | 159 (37.8) | 0.240 | 0.043 | −3.300 | −5.700 | 0.551 |
| Visits, mean (SD) | 0.66 (1.47) | 1.02 (2.50) | 0.54 (1.41) | 0.95 (2.30) | 0.034 | 0.493 | −0.100 | −0.100 | 0.730 |
| Annual migraine-related HCRU | |||||||||
| IP visits | |||||||||
| Patients, n (%) | 4 (1.0) | 8 (1.9) | 6 (1.4) | 3 (0.7) | 0.527 | 0.059 | 0.500 | −1.200 | 0.090 |
| Visits, mean (SD) | 0.01 (0.13) | 0.02 (0.14) | 0.01 (0.12) | 0.01 (0.16) | 0.782 | 0.366 | 0.002 | −0.007 | 0.415 |
| ED visits | |||||||||
| Patients, n (%) | 73 (17.3) | 88 (20.9) | 36 (8.6) | 58 (13.8) | < 0.001 | 0.002 | −8.800 | −7.100 | 0.589 |
| Visits, mean (SD) | 0.28 (1.09) | 0.32 (0.85) | 0.16 (1.14) | 0.24 (0.81) | < 0.001 | 0.086 | −0.100 | −0.100 | 0.354 |
| Acute migraine medication fills | |||||||||
| Patients, n (%) | 377 (89.5) | 353 (83.8) | 351 (83.4) | 347 (82.4) | 0.001 | 0.513 | −6.200 | −1.400 | 0.094 |
| Fills, mean (SD) | 8.73 (10.03) | 6.87 (8.01) | 7.24 (9.93) | 6.67 (8.25) | <0.001 | 0.513 | −1.500 | −0.200 | 0.002 |
| Preventive migraine medication fills | |||||||||
| Patients, n (%) | 380 (90.3) | 356 (84.6) | 322 (76.5) | 421 (100.0) | < 0.001 | < 0.001 | −13.800 | 15.400 | < 0.001 |
| Fills, mean (SD) | 9.3 (8.4) | 6.9 (6.7) | 7.5 (8.2) | 9.9 (7.6) | < 0.001 | < 0.001 | −1.800 | 3.000 | < 0.001 |
CGRP = calcitonin gene–related peptide; ED = emergency department; GMB = galcanezumab; HCRU = health care resource utilization; IP = inpatient; mAb = monoclonal antibody; SOC = standard of care.